Novo Nordisk announces a significant price reduction for its weight-loss medication, Wegovy, lowering the monthly cost to $499 for all doses. This initiative is part of the company’s new direct-to-consumer platform, NovoCare Pharmacy, which aims to enhance accessibility for uninsured or underinsured patients by offering home delivery services.
The price adjustment positions Wegovy more competitively within the rapidly expanding obesity treatment market, currently valued at $47.4 billion and projected to reach $471.1 billion by 2032. Novo Nordisk and Eli Lilly are anticipated to be major contributors to this growth.
Eli Lilly has also made strategic pricing changes to its weight-loss drug, Zepbound, reducing the cost of 2.5 mg and 5 mg vials to $349 and $499 per month, respectively. The company introduced 7.5 mg and 10 mg vials, priced at $499 per month, available exclusively through its LillyDirect Self Pay Pharmacy Solutions.
These pricing strategies emerge as the U.S. Food and Drug Administration (FDA) removes semaglutide, the active ingredient in Wegovy, from its shortage list, prompting compounding pharmacies to cease offering lower-cost versions. Novo Nordisk emphasizes the safety and efficacy of its FDA-approved product, cautioning against the use of non-approved compounded semaglutide.
The competition between Novo Nordisk and Eli Lilly reflects a broader trend in the pharmaceutical industry to make weight-loss treatments more affordable and accessible. Both companies’ efforts to reduce prices and offer direct-to-consumer options underscore their commitment to addressing the growing demand for effective obesity treatments.
Sources:
- Novo Nordisk introduces NovoCare® Pharmacy, lowering cost of all doses of FDA-approved Wegovy® (semaglutide) to $499 per month and offering easy home delivery for cash-paying patients
- Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients
- Novo Nordisk cuts Wegovy prices, following Eli Lilly on Zepbound
- Zepbound Is Now Available in Additional Doses at Lower Costs
- Hims Stock Claws Back After Novo Nordisk Undercuts It With A Cheaper Wegovy
- Novo Nordisk cuts Wegovy prices, following similar move by Zepbound-maker Eli Lilly
- Teladoc, LifeMD tie up with Lilly’s pharmacy partner to offer Zepbound
- Novo Nordisk Drops Price of Weight-Loss Drug Wegovy for Some Patients Paying Out of Pocket
- Eli Lilly Cuts Price of Weight-Loss Drug Zepbound for Self-Pay Patients
- Lilly offers weight-loss drugs in vials at a discount to fight competition
- Novo Nordisk
